SUN INITIATES PHASE II TRIAL OF COVID –
19 DRUG
Sun Pharmaceutical
Industries Ltd. has commenced the phase II clinical trial on AQCH, a
phytopharmaceutical (plant – derived ) drug for the treatment of COVID – 19
Received approval from
the Drugs Controller General of India (DCGI) for conducting the phase II clinical
trial in April this year
It is the first
phytopharmaceutical drug approved for clinical trials by the DCGI as a
potential treatment for COVID - 19
AQCH has shown anti
SARS-CoV – 2 effects in in-vitro studies conducted in collaboration with ECGEB.
AQCH is derived from tropical, climbing shrub cocculus hirsutus, which
is used in Asia for its apparent medicinal properties.
The company said the trial will be conducted across 12 centers in India
in 210 patients and a human safety study of the drug has been completed
"AQCH, which is being developed for dengue, has shown broad
antiviral effect in in-vitro studies and hence is being tested as a potential
treatment option for COVID-19," the company said in a statement.
Drugmakers around the world are rushing to develop a treatment or
vaccine for the fast-spreading novel
Two other Indian companies, Glenmark Pharmaceuticals Ltd and Strides
Pharma Science Ltd, are also conducting trials in India for potential COVID-19
treatments
The drugmaker has also received DCGI approval to start clinical trials
of pancreatitis drug nafamostat mesilate in COVID-19 patients.
No comments:
Post a Comment